Tsumura & Co.

4540

JP3535800001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-07 EDT			5-day change	1st Jan Change
3,962 ^JPY	+0.03%		+0.30%	+49.14%

05-09	Tsumura & Co. Announces Dividend for the Full Year Ended March 31, 2024, Scheduled Date to Commence Dividend Payments of June 28, 2024 and Provides Dividend Guidance for the Second Quarter of Fiscal 2025 and Year Ending March 31, 2025	CI
05-09	Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Fiscal 2025 and Year Ending March 31, 2025	CI

Tsumura & Co. Appoints Junichi Yoshii as Chairman, effective May 10, 2012

May 12, 2012 at 07:12 am

Tsumura & Co. has appointed Junichi Yoshii as Chairman. The effective date is May 10, 2012.

Latest news about Tsumura & Co.

Tsumura & Co. Announces Dividend for the Full Year Ended March 31, 2024, Scheduled Date to Commence Dividend Payments of June 28, 2024 and Provides Dividend Guidance for the Second Quarter of Fiscal 2025 and Year Ending March 31, 2025	05-09	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Fiscal 2025 and Year Ending March 31, 2025	05-09	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02-06	CI
Tsumura & Co. Announces Dividend for the second quarter ended September 30, 2023, Payable on December 5, 2023 and Provides Dividend Guidance for the Full Year Ending March 31, 2024	11-07	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half Ending September 30, 2023 and Full Year Ending March 31, 2024	23-08-03	CI
Tsumura & Co. Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024	23-08-03	CI
Tsumura's Fiscal 2023 Profit Falls 12.5%; Shares Slip 4%	23-05-10	MT
Tsumura & Co. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-09	CI
Tsumura & Co. Provides Consolidated Financial Guidance for the First Half and Full Year Ending March 31, 2024	23-05-09	CI
Tsumura & Co. Announces Year End Dividend for the Fiscal Year Ended March 31, 2023, and Provides Second Quarter and Year End Dividend Forecast for the Fiscal Year Ending March 31, 2024	23-05-09	CI
Kontafarma China Unit to Sell 66% Equity Interest of Shaanxi Unisplendour for 168.2 Million Yuan; Shares Slip 7%	23-04-14	MT
Robit, Inc. announced that it has received ¥499 million in funding from Tsumura & Co.	23-02-19	CI
Tsumura & Co. Provides Dividend Guidance for the Full Year Ending March 31, 2023	23-02-03	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-03	CI
Tsumura & Co. Announces Dividend for the Period Ended September 30, 2022, Payable on December 5, 2022 and Provides Dividend Guidance for the Full Year Ending March 31, 2023	22-11-04	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-11-04	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-08-05	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023	22-08-05	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023	22-05-10	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023	22-05-10	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	22-02-04	CI
Tsumura & Co. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022	22-02-04	CI
Tsumura & Co. Provides Earnings Guidance for the Year Ending March 31, 2022	21-11-05	CI
Tsumura & Co. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022	21-11-05	CI
Tsumura & Co's Attributable Profit Climbs 34% in Fiscal Q1	21-08-09	MT

TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.

Sector

Pharmaceuticals

Calendar

2024-11-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tsumura & Co.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3,962 JPY

Average target price

5,175 JPY

Spread / Average Target

+30.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TSUMURA & CO.	+49.14%	1.92B
ELI LILLY AND COMPANY	+45.82%	765B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B
PFIZER, INC.	-0.73%	162B

Other Pharmaceuticals

Tsumura & Co.

Equities

4540

JP3535800001

Pharmaceuticals

Tsumura & Co. Appoints Junichi Yoshii as Chairman, effective May 10, 2012

Latest news about Tsumura & Co.

Chart Tsumura & Co.

Company Profile

Income Statement Evolution

Ratings for Tsumura & Co.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals